"Receptors, Estrogen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
| Descriptor ID |
D011960
|
| MeSH Number(s) |
D12.776.826.750.350 D12.776.930.778.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Estrogen".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Estrogen".
This graph shows the total number of publications written about "Receptors, Estrogen" by people in this website by year, and whether "Receptors, Estrogen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 4 | 6 |
| 1997 | 9 | 4 | 13 |
| 1998 | 6 | 4 | 10 |
| 1999 | 7 | 7 | 14 |
| 2000 | 10 | 4 | 14 |
| 2001 | 14 | 6 | 20 |
| 2002 | 7 | 4 | 11 |
| 2003 | 10 | 5 | 15 |
| 2004 | 7 | 7 | 14 |
| 2005 | 12 | 9 | 21 |
| 2006 | 6 | 10 | 16 |
| 2007 | 9 | 4 | 13 |
| 2008 | 3 | 7 | 10 |
| 2009 | 6 | 11 | 17 |
| 2010 | 13 | 8 | 21 |
| 2011 | 7 | 11 | 18 |
| 2012 | 10 | 6 | 16 |
| 2013 | 5 | 8 | 13 |
| 2014 | 3 | 6 | 9 |
| 2015 | 10 | 7 | 17 |
| 2016 | 5 | 1 | 6 |
| 2017 | 3 | 9 | 12 |
| 2018 | 4 | 11 | 15 |
| 2019 | 3 | 5 | 8 |
| 2020 | 1 | 7 | 8 |
| 2021 | 3 | 7 | 10 |
| 2022 | 0 | 8 | 8 |
| 2023 | 1 | 8 | 9 |
| 2024 | 5 | 6 | 11 |
| 2025 | 2 | 5 | 7 |
| 2026 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Estrogen" by people in Profiles.
-
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials. Lancet Oncol. 2026 May; 27(5):592-603.
-
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer. ESMO Open. 2026 Apr; 11(4):106063.
-
Estrogen Induced Regulation of Mucosal-Associated Invariant T Cells in Asthma. J Immunol Res. 2026; 2026(1):e8201923.
-
Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer. CA Cancer J Clin. 2026 Jan-Feb; 76(1):e70055.
-
17?-Hydroxysteroid dehydrogenases 1 and 2: potential markers for breast cancer recurrence and tamoxifen resistance among premenopausal women diagnosed with breast cancer in Denmark. Breast Cancer Res. 2025 Dec 30; 28(1):28.
-
NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors. Sci Transl Med. 2025 Aug 27; 17(813):eadq5492.
-
Genetics-nutrition interactions control diurnal enhancer-promoter dynamics and liver lipid metabolism. Cell Metab. 2025 Oct 07; 37(10):1961-1979.e7.
-
Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2025 Jul; 212(1):71-78.
-
Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2- metastatic breast cancer: A Flatiron Health database analysis. Breast. 2025 Jun; 81:104448.
-
G protein-coupled oestrogen receptor regulates branched-chain amino acid metabolism through c-Jun N-terminal kinase. FEBS Lett. 2025 Mar; 599(6):892-900.